Drug developer CF PharmTech has raised $50m in an SAIC-backed series F round just six months after closing $90m in series E funding.
China-based respiratory disease treatment developer CF PharmTech raised $50m on Wednesday in a series F round that included SAIC Capital, the corporate venture capital arm of carmaker SAIC.
Investment manager China International Capital Corporation’s CICC Qichen and CICC Qide subsidiaries also took part in the round, as did BioTrack Capital, GP M&A Fund, Watson Investment, Passion Capital and Yuanming Capital.
Founded in 2007, CF PharmTech is working on therapeutics for asthma, rhinitis and chronic obstructive pulmonary disease. The latter is…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
